Safety of Drug-Eluting-Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunt
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Safety of Drug-Eluting-Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunt ; volume:02 ; number:02 ; year:2018 ; pages:071-075
Journal of Clinical Interventional Radiology ; 02, Heft 02 (2018), 071-075
- Contributor
-
Rief, Katherine
Pirasteh, Ali
Shenoy-Bhangl, Anuradha
Ganguli, Suvranu
Kalva, Sanjeeva P.
- DOI
-
10.1055/s-0038-1661001
- URN
-
urn:nbn:de:101:1-2019022407343223943046
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rief, Katherine
- Pirasteh, Ali
- Shenoy-Bhangl, Anuradha
- Ganguli, Suvranu
- Kalva, Sanjeeva P.
Other Objects (12)
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Pediatric Transjugular Intrahepatic Portosystemic Shunts
Transjugular Intrahepatic Portosystemic Shunt in Ascites: Updates
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial
Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus
Bile duct obstruction after transjugular intrahepatic portosystemic shunt implantation
Transarterial radioembolization vs transarterial chemoembolization with drug-eluting beads for treating hepatocellular carcinoma: a cost-effectiveness analysis in Japanese healthcare system
Transarterial Chemoembolization – Status Quo in Germany
Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis
Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma
Transjugular Intrahepatic Portosystemic Shunt Reduction for Medically Refractory Hepatic Encephalopathy
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Pediatric Transjugular Intrahepatic Portosystemic Shunts
Transjugular Intrahepatic Portosystemic Shunt in Ascites: Updates
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial
Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus
Bile duct obstruction after transjugular intrahepatic portosystemic shunt implantation
Transarterial radioembolization vs transarterial chemoembolization with drug-eluting beads for treating hepatocellular carcinoma: a cost-effectiveness analysis in Japanese healthcare system
Transarterial Chemoembolization – Status Quo in Germany
Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis
Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma
Transjugular Intrahepatic Portosystemic Shunt Reduction for Medically Refractory Hepatic Encephalopathy
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Pediatric Transjugular Intrahepatic Portosystemic Shunts
Transjugular Intrahepatic Portosystemic Shunt in Ascites: Updates
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial
Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus
Bile duct obstruction after transjugular intrahepatic portosystemic shunt implantation
Transarterial radioembolization vs transarterial chemoembolization with drug-eluting beads for treating hepatocellular carcinoma: a cost-effectiveness analysis in Japanese healthcare system
Transarterial Chemoembolization – Status Quo in Germany
Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis
Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma